Participants in the study will be assigned to receive either linaprazan glurate or lansoprazole. Because the study uses a double-dummy method to ensure that neither the researchers nor the participants know which medication is being taken, some individuals will receive combinations of the active medication and a placebo. The treatment involves taking tablets by oral use over a period of time to see how well the esophagus remains healed and to monitor any potential side effects.

The purpose of this research is to determine if linaprazan glurate is more effective than lansoprazole in healing erosive esophagitis. Some participants will receive linaprazan glurate tablets, while others will receive lansoprazole capsules. Some participants will receive placebo. The treatment will continue for up to 8 weeks.

During the study, doctors will examine the healing of the food pipe using a thin, flexible tube with a camera that allows them to see the condition of the esophagus. Participants will also need to keep track of their symptoms, particularly heartburn, using an electronic diary. The study will monitor any side effects that occur during the treatment period.

The purpose of this study is to evaluate how safe almagate is for both the pregnant women and their babies. The study will observe the effects of almagate on the mothers and their babies during pregnancy and after birth. Participants will take almagate for a period of up to 14 days. Throughout the study, doctors will monitor the health of the mothers and their babies, looking at various factors such as the type of delivery, the baby’s weight and length at birth, and the overall health of the newborn. The study will also assess the mothers’ satisfaction with the use of almagate as an antacid.

Participants will have regular follow-up visits with their healthcare providers to discuss their experiences with almagate and any changes in their symptoms. The study aims to provide valuable information on the safety of using almagate during pregnancy, which can help guide future treatment options for pregnant women experiencing heartburn and reflux.

The purpose of the study is to investigate how well a cow’s milk-free diet or Omeprazole works in reducing the symptoms of GERD in infants under one year of age. During the study, parents will be asked to record the number of reflux episodes their child experiences each week using an app. This will help researchers understand how the treatment affects the frequency of reflux episodes. The study will last for several weeks, and parents will be required to monitor and report any changes in their child’s symptoms, such as crying, discomfort, or feeding difficulties.

Throughout the study, the safety and any side effects of Omeprazole will be closely monitored. Parents will report any adverse events, such as stomach pain or nausea, that their child may experience. Additionally, the study will assess changes in the child’s weight and any signs of improvement in symptoms related to GERD and cow’s milk allergy. The trial aims to provide valuable information on the effectiveness of Omeprazole and dietary changes in managing GERD in infants.

The purpose of this study is to assess the safety and effectiveness of Dexlansoprazole in treating children with GERD. Participants will receive the medication daily for a period of 12 weeks. The study will compare different doses of the medication to see which is most effective in reducing symptoms like stomach pain, burning in the chest or throat, and other related discomforts. Some participants may receive a placebo, which looks like the real medication but does not contain the active ingredient.

Throughout the study, researchers will monitor the participants to see how many days they experience relief from symptoms such as stomach pain, burning sensations, vomiting, and trouble eating. The goal is to find out how well Dexlansoprazole works in improving the quality of life for children with GERD. The study will also look at how the medication affects different age groups within the 2 to 11-year-old range. This information will help doctors understand how to better treat GERD in children.

The purpose of this research is to determine if prucalopride, when added to existing acid-reducing therapy, can help reduce acid reflux in patients whose symptoms are not fully controlled by standard treatment. The study will compare prucalopride tablets to placebo tablets over a period of 4 weeks while patients continue their regular acid-reducing medication.

During the study, participants will take either prucalopride or placebo once daily for 8 weeks. Various tests will be performed to measure the amount of acid reflux and how well the food pipe is working. Participants will also complete questionnaires about their symptoms. The total amount of prucalopride that could be taken during the study period will not exceed 150 mg.

The purpose of the study is to evaluate how effective citalopram is when added to the current treatment for these patients. Participants will take citalopram 20 mg daily for eight weeks. The study will monitor changes in the number of reflux episodes, the volume of reflux, and the severity of symptoms. It will also assess how sensitive the esophagus is to reflux and use questionnaires to understand the impact of the treatment on symptoms.

Participants will be randomly assigned to receive either citalopram or a placebo, which looks like the medication but does not contain the active ingredient. The trial will last for a total of 16 weeks, including the treatment period and follow-up. The study aims to provide insights into whether citalopram can be a beneficial addition to the treatment of GERD symptoms in patients who do not fully respond to standard PPI therapy.